Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657269 | 0.89 | TSHR (0.36) | HSD11B1 | |
| SCHEMBL14204101 | 0.85 | SMPD1 (0.34) | — | |
| SCHEMBL5655726 | 0.83 | KDM4E (0.31) | — | |
| SCHEMBL11843852 | 0.82 | HSD11B1 (0.37) | HSD11B1 | |
| SCHEMBL19538769 | 0.74 | MEN1 (0.36) | HSD11B1 | |
| SCHEMBL19538754 | 0.73 | MAPT (0.34) | HSD11B1 | |
| SCHEMBL5654447 | 0.73 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL11640330 | 0.73 | — | — | |
| SCHEMBL11380910 | 0.72 | TSHR (0.38) | HSD11B1 | |
| SCHEMBL14204006 | 0.72 | POLB (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567028-B1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | MEDSHINE DISCOVERY INC (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2020-07-16 | — | — | US | disclosed |
| EP-3567028-A1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1593673-A1 | ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | CCR2, CCR5, CCRL2 | HSD11B1 562/4885 |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | CCR2, CCR5, CCRL2 | HSD11B1 562/4885 |
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | CCR5, MSR1, CCR2 | HSD11B1 767/4885 |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | HSD11B1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.